The Innovative Medicines Initiative (IMI)
The ERA4TB project is funded by the Innovative Medicines Initiative (IMI), a large-scale public-private partnership between the European Union and the pharmaceutical industry association EFPIA.
IMI aims to boost biopharmaceutical innovation in Europe and to speed up the development of better and safer medicines for patients. Through its unique and innovative funding scheme, IMI supports research projects in the areas of safety and efficacy, knowledge management and education and training.
In addition to the large biopharmaceutical companies, the participating research consortia include small- and medium-sized enterprises, patient organisations, academia and other research organisations, hospitals and public authorities.
The European Commission’s Seventh Framework Programme contributes €1 billion to the IMI research programme. That amount is matched by in kind contributions worth at least another €1 billion from the pharmaceutical companies that are members of EFPIA, the European Federation of Pharmaceutical Industries and Associations.